Rental revenue dropped from $55.3 million in the fourth quarter of 2023 to $47.5 in the same period of 2024, a 14.1-percent ...

Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).

BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in ...

Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects.

Beam Therapeutics (BEAM) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical ...

Malayalam film Level Cross won the Second Best Indian Film award at the 16th Bangalore International Film Festival (BIFFes) ...